Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J Warren

Showing results (81-90 of 88) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 88 results.
Cell Reports. Medicine|September 9, 2025
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumorsRafaela Abrantes, Christopher Forcados, David J Warren, et al.
RMD Open|November 3, 2022
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapySilje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
The Lancet. Rheumatology|November 23, 2022
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort studyKristin H Bjørlykke, Hilde S Ørbo, Anne T Tveter, et al.
Bioelectronic Medicine|October 24, 2025
The auditory nerve implant-concept and device description of a novel electrical auditory prosthesisThomas Lenarz, Florian Solzbacher, Loren Rieth, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 4, 2022
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive TherapySilje W Syversen, Ingrid Jyssum, Anne T Tveter, et al.
The Lancet. Rheumatology|January 3, 2022
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort studyIngrid Jyssum, Hassen Kared, Trung T Tran, et al.
Bioelectronic Medicine|December 30, 2025
Correction: The auditory nerve implant-concept and device description of a novel electrical auditory prosthesisThomas Lenarz, Florian Solzbacher, Loren Rieth, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 23, 2020
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension TrialsKristin K Jørgensen, Guro L Goll, Joe Sexton, et al.
Pageof 9

Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Cell Reports. Medicine|September 9, 2025
Pan-carcinoma sialyl-Tn-targeting expands CAR therapy to solid tumorsRafaela Abrantes, Christopher Forcados, David J Warren, et al.
RMD Open|November 3, 2022
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapySilje Watterdal Syversen, Ingrid Jyssum, Anne Therese Tveter, et al.
The Lancet. Rheumatology|November 23, 2022
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort studyKristin H Bjørlykke, Hilde S Ørbo, Anne T Tveter, et al.
Bioelectronic Medicine|October 24, 2025
The auditory nerve implant-concept and device description of a novel electrical auditory prosthesisThomas Lenarz, Florian Solzbacher, Loren Rieth, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 4, 2022
Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive TherapySilje W Syversen, Ingrid Jyssum, Anne T Tveter, et al.
The Lancet. Rheumatology|January 3, 2022
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort studyIngrid Jyssum, Hassen Kared, Trung T Tran, et al.
Bioelectronic Medicine|December 30, 2025
Correction: The auditory nerve implant-concept and device description of a novel electrical auditory prosthesisThomas Lenarz, Florian Solzbacher, Loren Rieth, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 23, 2020
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension TrialsKristin K Jørgensen, Guro L Goll, Joe Sexton, et al.
Pageof 9